These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 30054764)
1. Ecological effects of cefepime use during antibiotic cycling on the Gram-negative enteric flora of ICU patients. Venturini C; Ginn AN; Wilson BE; Tsafnat G; Paulsen I; Partridge SR; Iredell JR Intensive Care Med Exp; 2018 Jul; 6(1):19. PubMed ID: 30054764 [TBL] [Abstract][Full Text] [Related]
2. Cefepime use in a pediatric intensive care unit reduces colonization with resistant bacilli. Toltzis P; Dul M; O'Riordan MA; Salvator A; Rosolowski B; Toltzis H; Blumer JL Pediatr Infect Dis J; 2003 Feb; 22(2):109-14. PubMed ID: 12586972 [TBL] [Abstract][Full Text] [Related]
7. The effects of antibiotic cycling and mixing on antibiotic resistance in intensive care units: a cluster-randomised crossover trial. van Duijn PJ; Verbrugghe W; Jorens PG; Spöhr F; Schedler D; Deja M; Rothbart A; Annane D; Lawrence C; Nguyen Van JC; Misset B; Jereb M; Seme K; Šifrer F; Tomiç V; Estevez F; Carneiro J; Harbarth S; Eijkemans MJC; Bonten M; Lancet Infect Dis; 2018 Apr; 18(4):401-409. PubMed ID: 29396000 [TBL] [Abstract][Full Text] [Related]
8. In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime. Pires J; Taracila M; Bethel CR; Doi Y; Kasraian S; Tinguely R; Sendi P; Bonomo RA; Endimiani A Antimicrob Agents Chemother; 2015 Dec; 59(12):7483-8. PubMed ID: 26392491 [TBL] [Abstract][Full Text] [Related]
9. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. Livermore DM; Mushtaq S; Warner M; Vickers A; Woodford N J Antimicrob Chemother; 2017 May; 72(5):1373-1385. PubMed ID: 28158732 [TBL] [Abstract][Full Text] [Related]
10. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
11. Antimicrobial activity of cefepime tested against Bush group I beta-lactamase-producing strains resistant to ceftazidime. A multilaboratory national and international clinical isolate study. Jones RN; Marshall SA Diagn Microbiol Infect Dis; 1994 May; 19(1):33-8. PubMed ID: 7956010 [TBL] [Abstract][Full Text] [Related]
12. Influence of extended-spectrum beta-lactams on gram-negative bacterial resistance. Paladino JA; Sunderlin JL; Singer ME; Adelman MH; Schentag JJ Am J Health Syst Pharm; 2008 Jun; 65(12):1154-9. PubMed ID: 18541686 [TBL] [Abstract][Full Text] [Related]
13. Extended-spectrum β-lactamase, plasmid-mediated AmpC β-lactamase, fluoroquinolone resistance, and decreased susceptibility to carbapenems in Ruh E; Zakka J; Hoti K; Fekrat A; Guler E; Gazi U; Erdogmus Z; Suer K Antimicrob Resist Infect Control; 2019; 8():98. PubMed ID: 31198531 [TBL] [Abstract][Full Text] [Related]
14. ICU Acquisition Rate, Risk Factors, and Clinical Significance of Digestive Tract Colonization With Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae: A Systematic Review and Meta-Analysis. Detsis M; Karanika S; Mylonakis E Crit Care Med; 2017 Apr; 45(4):705-714. PubMed ID: 28157141 [TBL] [Abstract][Full Text] [Related]
15. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae. Tamma PD; Girdwood SC; Gopaul R; Tekle T; Roberts AA; Harris AD; Cosgrove SE; Carroll KC Clin Infect Dis; 2013 Sep; 57(6):781-8. PubMed ID: 23759352 [TBL] [Abstract][Full Text] [Related]
16. Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group. Jones RN; Pfaller MA; Doern GV; Erwin ME; Hollis RJ Diagn Microbiol Infect Dis; 1998 Mar; 30(3):215-28. PubMed ID: 9572029 [TBL] [Abstract][Full Text] [Related]
17. Activity of imipenem/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015-2016. Lob SH; Hoban DJ; Young K; Motyl MR; Sahm DF J Glob Antimicrob Resist; 2018 Dec; 15():12-19. PubMed ID: 29857057 [TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of cefepime and other broad-spectrum beta-lactams in Taiwan medical centers. The Taiwan Antimicrobial Resistance Study Group. Biedenbach DJ; Johnson DM; Jones RN Diagn Microbiol Infect Dis; 1999 Dec; 35(4):299-305. PubMed ID: 10668589 [TBL] [Abstract][Full Text] [Related]
19. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. Burgess DS; Frei CR J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664 [TBL] [Abstract][Full Text] [Related]
20. In-vitro activity of cefepime and other broad-spectrum antimicrobials against several groups of gram-negative bacilli and Staphylococcus aureus. Tallis E; Rudensky B; Attias D; Raveh D; Schlesinger Y; Yinnon AM Diagn Microbiol Infect Dis; 1999 Oct; 35(2):121-6. PubMed ID: 10579092 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]